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Abstract
Novel immunotherapies for oncologic treatment include anti-programmed cell
death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) agents. These therapies
activate the body’s inherent immune response against tumor cells by stimulating T cell
proliferation. With the recent approval of agents such as nivolumab and pembrolizumab
for the treatment of melanoma, lung cancer, and renal cell cancer, there is a growing need
to better characterize their toxicity profiles. This study sought to provide a clinical and
histologic description of the cutaneous toxicities seen in patients receiving anti-PD-1/PDL1 treatment. Cases of patients on anti-PD-1/PD-L1 therapy who developed cutaneous
adverse effects were collected from a single tertiary care hospital from 2010 to 2015.
Data regarding demographics of patients, concurrent medications, therapeutic regimen,
clinical morphology of cutaneous lesions, and tumor response were collected. A total of
20 patients were included in the study, with the majority of patients being treated with
nivolumab alone. The majority of cases had a clinical morphology consisting of
erythematous papules with scale in a variety of distributions and associated pruritus.
Most cases were treated with topical corticosteroids and did not require discontinuation
of oncologic treatment. Out of six patients with lung cancer who were treated with an
anti-PD-1/PD-L1 agent alone, five patients (83%) responded to treatment. Nearly all
cases for which biopsies were available (16 of 17 cases, 94%) showed features of
lichenoid interface dermatitis. In addition, 47% of the cases (8 of 17) showed features of
spongiotic dermatitis. These results support a cutaneous reaction associated with anti-PD1/PD-L1 therapies that has distinct clinical and histologic features.
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Introduction
Immunotherapy represents the next generation of anti-cancer therapy. With
genetic, cellular, and biochemical advances, numerous immunomodulating agents have
emerged as the most effective treatment options for cancer patients within the last several
years. This represents a shift from targeting specific molecules important in
tumorigenesis to disinhibiting the natural anti-tumor immune response. The idea of
immunosurveillance was first developed in the 1950s by immunologists F. Macfarlane
Burnet and Lewis Thomas, who both believed that immune cells of the body constantly
surveyed host tissues for transformed tumorigenic cells (1, 2). This hypothesis was
briefly challenged when animal models showed no differences of carcinogen-induced
tumor development between normal and athymic mice (3). However, in the late 20th
century, this theory was reignited when the immune response, and specifically the role of
interferon-gamma, was found to be essential in preventing the development of
carcinogen-induced tumors in a mouse model (4). Further support came from the clinical
observation of higher incidences of specific types of cancer in immunodeficient
individuals (5), as well as studies in the late 1990s and early 2000s that showed that the
presence of an inflammatory lymphocytic infiltrate in a tumor correlated with increased
patient survival in a variety of different cancers (6).
However, the picture is more complicated, as cancers frequently arise in
immunocompetent individuals. It is thought that the immune system may also
paradoxically allow for the emergence of tumor cells that are able to escape immune
recognition, which was first recognized in mice models when a large percentage of
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tumors isolated from normal mice had changed to progressively growing tumors, whereas
none of the tumors isolated from athymic mice showed this behavior (7). This has led to
the more nuanced concept of cancer immunoediting, which encompasses both the
protective and the tumor-sculpting functions of the immune system. This theory proposes
three phases in which the tumor interacts with the host system: 1) elimination, during
which the immune system is able to eradicate nascent tumor cells; 2) equilibrium, during
which the immune system controls tumor expansion and metastasis; and finally 3) escape,
during which tumor cells have now developed resistance to the host immune system (8).
Communication between the cells of the immune system and tumor cells is
complex and tightly controlled via a number of cell-cell receptor-ligand interactions, as
well as released cytokine factors. The adaptive immune system is comprised of T
lymphocytes which learn to distinguish various self-structures from non-self structures
via the major histocompatibility complex (MHC) system, and B lymphocytes which
recognize antigens via immunoglobulins. In the innate immune system, there are natural
killer (NK) cells which recognize the lack of expression of self. Furthermore, antigenpresenting cells can recognize non-self structures and further activate adaptive cellular
and humoral responses. As an added regulatory step, T cell activation requires not only
the interactions between the T cell receptor and peptide-MHC complexes, but also costimulation with receptors such as CD28, which binds to either B7-1 (CD80) or B7-2
(CD86) (9). In addition, there are also negative co-stimulatory molecules, such as
cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1).
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CTLA-4 Therapy
CTLA-4 is normally expressed at low levels on the surface of naïve T cells and
acts by competing with CD28 by binding to CD80 and CD86 (10), which effectively
shuts off T cell receptor signaling. Mouse models demonstrated that injection with a
solubilized form of CTLA-4 suppressed T cell-dependent antibody responses to
exogenous antigens (11). Treatment with an anti-CTLA-4-blocking antibody caused
regression of tumors in mouse models of colon carcinoma, fibrosarcoma, ovarian
carcinoma, and prostate cancer (12-14).
Given the importance of CTLA-4 as an immune checkpoint mediator in
preclinical animal models, monoclonal antibodies for clinical use in oncologic treatment
have been developed. One such antibody that blocks CTLA-4 is ipilimumab, which has
been studied most extensively in melanoma. Ipilimumab binds to CTLA-4 with a greater
affinity than its endogenous ligands, CD80 and CD86, and in this way is able to
dysregulate the immune response. Early phase I and II trials of ipilimumab as
monotherapy in patients with melanoma showed clinical efficacy. In a phase I/II study of
88 patients with unresectable stage 3 and 4 melanoma, ipilimumab was administered in
single doses up to 20 mg/kg, multiple doses up to 5 mg/kg, and multiple doses up to 10
mg/kg (15). Ipilimumab had activity with a disease control rate of 19%. A larger,
randomized phase II trial involved 217 patients with stage 3 or 4 melanoma, who were
administered 10, 3, or 0.3 mg/kg of ipilimumab every 3 weeks for four cycles followed
by maintenance every 3 months (16). The overall response rate (ORR) in this trial,
defined by the patients who showed either a complete or partial response to treatment,
was 11.1% for 10 mg/kg, 4.2% for 3 mg/kg, and 0% for 0.3 mg/kg.
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The first randomized phase III trial compared ipilimumab alone versus
ipilimumab in combination with a gp100 melanoma peptide vaccine versus the peptide
vaccine alone, in patients with pretreated melanoma (17). Ipilimumab was given at a dose
of 3 mg/kg every 3 weeks for four cycles. A total of 676 patients were included and the
best overall response rates were 10.9%, 5.7%, and 1.5% in patients receiving ipilimumab
alone, ipilimumab plus the vaccine, and the vaccine alone, respectively.
A second phase III trial randomized 502 previously untreated stage 3 or 4
metastatic melanoma patients to receive dacarbazine in combination with either
ipilimumab 10 mg/kg or placebo (18). A highly statistically significant improvement in
median survival from 9.1 to 11.2 months was observed in patients receiving both
ipilimumab and dacarbazine. In addition, the overall response rates were higher for
ipilimumab and dacarbazine at 15.2%, compared to 10.3% in patients receiving
dacarbazine alone. These two phase III trials demonstrated that ipilimumab had
significant clinical efficacy in patients with advanced melanoma. In 2011, the FDA
approved ipilimumab at a dose of 3 mg/kg for the treatment of patients with unresectable
or metastatic melanoma.

Anti-CTLA-4 Adverse Effects
From clinical trials in which patients were treated with ipilimumab monotherapy,
it appears that the most common adverse events of any grade reported in these patients
include fatigue (12 to 56% of patients), diarrhea (12 to 46%), nausea (11 to 35%), rash
(15 to 35%), and pruritus (15 to 35%) (16, 17, 19-21). A large proportion of adverse
effects associated with ipilimumab therapy appear to be immune-related, and these
immune-related adverse effects (irAEs) occur with an incidence of between 60 to 78%
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for any grade toxicity (17, 18, 22). The incidence of grade 3 or 4 irAEs ranges anywhere
between 7 to 56% (23). The most common organ systems affected include the skin and
the gastrointestinal system, with symptoms including rash, pruritus, colitis, and diarrhea.
Less common toxicities involve the liver and endocrine organs, such as hypothyroidism,
adrenal insufficiency, and hypophysitis. There appears to be a direct correlation between
ipilimumab dose and irAE frequency and grade (16). While the majority of clinical data
has come from studies investigating the use of ipilimumab in melanoma, a smaller study
investigating ipilimumab in prostate cancer patients found similar incidences of irAEs.
The most common grade 3 and 4 toxicities included enterocolitis (15.9%, 7 of 44
patients), hypopituitarism (13.6%, 6 of 44), hepatitis (9.1%, 4 of 44), and dermatitis
(6.8%, 3 of 44) (24).
Out of a large pooled analysis of multiple ipilimumab clinical trials involving
1498 patients, dermatologic adverse effects were the most common irAE of any grade
with an incidence of 44.9% (22). The majority of these irAEs were of grade 1 or 2 in
severity. In terms of cutaneous toxicities specifically, the most common adverse effects
were reported as rash and pruritus. A meta-analysis of 19 trials testing ipilimumab at
various doses representing 760 patients total found an overall incidence of rash of any
grade to be 24% (25). The overall incidence of high-grade rash was 2.4% and there was
no statistical difference in the risk of rash based on dose or underlying tumor. Skin
reactions in response to ipilimumab consist primarily of discrete, pruritic, erythematous
papules that coalesce into thin plaques on the trunk and extensor surfaces of extremities
(26). The rash and pruritus are typically mild in severity, can be managed with topical
steroids and/or oral antihistamines, and are usually reversible (27). Ipilimumab treatment
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typically does not need to be modified or discontinued. On histology, these lesions show
perivascular infiltrates in the superficial dermis that can be comprised of both
lymphocytes and eosinophils (26, 27). These lymphoid aggregates are composed of a
mixture of CD4+ and CD8+ T cells. The exact mechanism leading to irAEs with
ipilimumab treatment is not well understood. However, these findings suggest that
immune cell infiltration may be playing a role at specific sites of toxicity. Indeed, in
patients who develop colitis with ipilimumab treatment, biopsy of the colon demonstrates
infiltration of neutrophils, T lymphocytes, and plasma cells (28).

PD-1 Therapy
In addition to CTLA-4, another immunoregulatory molecule that has emerged as a
therapeutic target is programmed cell death-1 (PD-1). Like CTLA-4, it is involved in
regulating the delicate balance between immune activation and tolerance. PD-1 is a
receptor that is expressed on both activated T and B cells, as well as monocytes (29). PD1 has two ligands: programmed cell death ligand-1 (PD-L1) and 2 (PD-L2), which are
normally found on antigen-presenting cells, tumor cells, or other cells in the
inflammatory microenvironment (29). Binding of PD-1 with its ligands leads to the
inhibition of T cell proliferation and cytokine secretion. PD-L1 is often aberrantly
expressed on tumors, which therefore allows for tumor-induced immune suppression by
downregulating the T cell response. Furthermore, increased expression of PD-L1 in
tumors was found to correlate with both decreased CD8+ T-cell infiltrate within the
tumor, as well as with worse clinical outcome in patients in a variety of cancers,
including ovarian, pancreatic, bladder, kidney, and melanoma (30-34). By inhibiting the
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PD-1 receptor and blocking its interactions with its ligands, this allows for activation of
an antitumor immune response.

Nivolumab
An initial phase I trial of an anti-PD-1 antibody, MDX 1106, which would later be
renamed as nivolumab, included 39 patients with advanced metastatic melanoma,
colorectal cancer, prostate cancer, non-small cell lung cancer (NSCLC), or renal cell
carcinoma (RCC), who received treatment at doses between 0.3, 1, 3, or 10 mg/kg (35).
This trial demonstrated that the therapy was well-tolerated. One patient with colorectal
carcinoma achieved complete response, and two patients with RCC and melanoma
experienced partial responses. Among nine of these patients whose biopsies were studied,
PD-L1 expression on tumor cells appeared to correlate with the likelihood of tumor
regression following treatment with PD-1 blockade. Furthermore, one patient with
melanoma who underwent pre- and post-treatment biopsies of an axillary lymph node
metastasis showed subsequent tumor regression after treatment accompanied by a
moderate infiltration of CD8+ T cells that were not present prior to treatment. A
subsequent phase II study investigated 21 patients with treatment-refractory metastatic
NSCLC, RCC, melanoma, or prostate cancer who received MDX-1106 (36). In this study,
one patient with RCC had a partial response, and regression of individual lesions with
mixed overall responses was seen in two melanoma patients. Biopsy of a regressing
lymph node metastasis showed again a moderately increased CD8+ T cell infiltrate after
treatment.
Over the last several years, many large-scale clinical trials have now been done. A
phase I trial of nivolumab in 296 patients that included patients with melanoma, non-
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small cell lung cancer, renal cell carcinoma, prostate cancer, and colorectal cancer, found
objective responses in those with NSCLC, melanoma, or RCC (37). Cumulative response
rates were 18% among patients with NSCLC (14 of 76 patients), 28% among patients
with melanoma (26 of 94 patients), and 27% among patients with RCC (9 of 33 patients).
The responses were especially durable, with 20 of 31 responses (65%) lasting one year or
more. A separate phase I trial that studied nivolumab only in melanoma, with 107
previously treated, anti-CTLA-4-naïve patients found similar results, with an objective
response rate of 31% and median response duration of 2 years (38). The overall survival
was 16.8 months, with a median progression-free survival of 3.7 months.
In a phase III study (CheckMate 066), 418 patients with previously untreated
melanoma negative for the BRAF mutation were randomized to receive either nivolumab
or dacarbazine (39). The primary endpoint measured was overall survival. At one year,
the overall rate of survival was 72.9% in the nivolumab group compared to 42.1% in the
dacarbazine group. The median progression-free survival was 5.1 months in the
nivolumab group versus 2.2 months in the dacarbazine group. Furthermore, the objective
response rate was 40% in the nivolumab group compared to 13.9% in the dacarbazine
group. There was a survival benefit with nivolumab regardless of whether or not PD-L1
was expressed in tumor cells.
A separate phase III trial (CheckMate 037) looked at patients who had advanced
melanoma with progression after either ipilimumab or a BRAF inhibitor if positive for a
BRAF mutation (40). 631 patients were screened, with 272 patient randomized to receive
nivolumab and 133 patients to receive investigator’s choice of chemotherapy. Objective
responses were reported in 38 of the first 120 patients (31.7%) in the nivolumab group
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versus 10.6% (5 of 47 patients) in the investigator’s choice of chemotherapy group,
showing that nivolumab led to a greater proportion of patients achieving a response.
In addition to melanoma, clinical trials in patients with other malignancies have
been done, including non-small cell lung cancer. A study investigating the overall
survival and long-term safety of nivolumab in patients with previously treated NSCLC
showed an objective response rate of 17% (22 of 129 patients) (41). Out of this study
group, the median progression-free survival was 2.3 months and overall survival was 9.9
months. A separate study (CheckMate 063) investigating 117 patients specifically with
squamous NSCLC found similar results, with a response rate of 14.5%, a median
progression-free survival of 1.9 months, and overall survival of 8.2 months (42).
A larger trial (CheckMate 017) also investigated the use of nivolumab in patients
with advanced squamous cell NSCLC with disease progression on previous treatment
compared to standard chemotherapy (43). A total of 272 patients were randomized to
receive either nivolumab or docetaxel. The median overall survival was 9.2 months with
nivolumab versus 6.0 months with docetaxel. The response rate was 20% with nivolumab
compared to 9% with docetaxel, and the median progression-free survival was 3.5
months with nivolumab versus 2.8 months with docetaxel. The study further found that
the expression of PD-L1 in the tumor was neither prognostic nor predictive of benefit.
As for nonsquamous NSCLC, a phase III study (CheckMate 057) randomized
patients who had progressed after previous platinum-based chemotherapy to receive
either nivolumab or docetaxel (44). Median overall survival was longer with nivolumab
than with docetaxel, with 12.2 months among 292 patients in the nivolumab group versus
9.4 months among 290 patients in the docetaxel group. The response rate was 19% with
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nivolumab versus 12% with docetaxel. Although progression-free survival did not favor
nivolumab over docetaxel (median, 2.3 months and 4.2 months, respectively), the rate of
progression-free survival at one year was higher with nivolumab than with docetaxel
(19% and 8%, respectively).
In addition to melanoma and lung cancer, nivolumab has also been shown to have
activity in renal cell carcinoma. An early phase I study in 34 patients with previously
treated RCC found 10 patients (29%) who achieved objective responses (45). These
responses were particularly durable, with a median response duration of 12.9 months.
Median overall survival in all patients was 22.4 months. A phase II study of patients with
metastatic RCC randomized patients to receive varying dosages of nivolumab of either
0.3, 2, or 10 mg/kg (46). The median overall survival was 18.2 months in the 0.3 mg/kg
group, 25.5 months in the 2 mg/kg group, and 24.7 months in the 10 mg/kg group.
Progression-free survival and response rate showed similar trends. Median progressionfree survival was 2.7, 4.0, and 4.2 months respectively. Response rates were 20%, 22%,
and 20%, respectively. While no clear dose-response relationship was detected, these
results showed that nivolumab demonstrated antitumor activity across all three dosages
studied.
Most recently, a large phase III trial (CheckMate 025) was done involving 821
patients with advanced RCC who had received previous treatment (47). Patients were
randomized to receive either nivolumab or everolimus as treatment. The median overall
survival was 25.0 months with nivolumab compared to 19.6 months with everolimus. The
objective response rate was greater with nivolumab than with everolimus (25% versus
5%, respectively). The median progression-free survival was 4.6 months with nivolumab
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and 4.4 months with everolimus. This clinical trial was actually stopped early given the
clinical benefit in overall survival shown with nivolumab.
Given the results of these numerous clinical trials that demonstrate the improved
clinical benefit of nivolumab compared to previous therapies, nivolumab was approved in
2014 for patients with previously treated unresectable or metastatic melanoma. It was
also approved in 2015 for the treatment of patients with metastatic squamous non-small
cell lung cancer with progression on or after platinum-based chemotherapy. In late 2015,
nivolumab was approved to treat patients with advanced renal cell carcinoma. Table 1
summarizes the results of the clinical trials that have been done investigating nivolumab
in various malignancies.

Pembrolizumab
A second antibody that inhibits PD-1 has been developed, called pembrolizumab,
also previously known as MK-3475, and appears to have comparable efficacy and
tolerability. Early clinical trials demonstrated its activity in melanoma patients. A study
of 135 patients with advanced melanoma showed a response rate of 38% with no
significant difference between patients who had received prior treatment with ipilimumab
and those who had not (48). The overall median progression-free survival among these
patients was longer than 7 months. A separate phase I trial of 411 patients, of which 190
were naïve to ipilimumab and 221 had been previously treated with ipilimumab, did find
a difference between these two patient groups (49). In the ipilimumab-treated group, the
overall response rate was found to be 28% and in ipilimumab-naïve patients, the response
rate was 40%. The median progression-free survival was similar in both groups, at 6
months in ipilimumab-naïve patients and 5.8 months in ipilimumab-treated patients. A

Melanoma

Melanoma
Melanoma
Melanoma
NSCLC
Squamous
NSCLC
Squamous
NSCLC
Nonsquamous
NSCLC
RCC
RCC
RCC

107

210
272
316
129
117
135
292

34
168
406

Topalian et al. 2014
(38)

Robert et al. 2015
(CheckMate 066) (39)

Weber et al. 2015
(CheckMate 037) (40)

Larkin et al. 2015
(CheckMate 067) (21)

Gettinger et al. 2015
(41)

Rizvi et al. 2015
(CheckMate 063) (42)

Brahmer et al. 2015
(CheckMate 017) (43)

Borghaei et al. 2015
(Checkmate 057) (44)

McDermott et al. 2015
(45)

Motzer et al. 2015 (46)

Motzer et al. 2015
(Checkmate 025) (47)

20,
22,
20%A
25%

29%

19%

20%

15%

17%

44%

32%

40%

31%

ORR

25.0

18.2, 25.5,
24.7A

2.7, 4.0, 4.2A
4.6

22.4

12.2

9.2

8.2

9.9

Not yet
reported

Not yet
reported

Not
reached

16.8

Median
OS (mo)

7.3

2.3

3.5

1.9

2.3

6.9

4.7

5.1

3.7

Median PFS
(mo)

Fatigue (41%)
Rash (27%)
Diarrhea (18%)
Fatigue (22-35%)
Rash (22-28%)
Nausea (10-13%)
Fatigue (33%)
Nausea (14%)
Pruritus (14%)

Fatigue (32%)
Rash (23%)
Diarrhea (18%)
Fatigue (20%)
Pruritus (17%)
Nausea (17%)
Fatigue (25%)
Pruritus (16%)
Diarrhea (11%)
Fatigue (34%)
Rash (25%)
Diarrhea (19%)
Fatigue (24%)
Decreased appetite (12%)
Diarrhea (10%)
Fatigue (33%)
Decreased appetite (19%)
Nausea (15%)
Fatigue (16%)
Decreased appetite (11%)
Asthenia (10%)
Fatigue (16%)
Nausea (12%)
Decreased appetite (10%)

Most Common Adverse
Events (% incidence)

10%

9, 4, 13%A

27%

9%

4%

11%

7%

22%

9%

15%

23%

Rash

14%

10, 5,
11%A

18%

8%

2%

6%

9%

19%

16%

17%

13%

Pruritus

-

-

-

-

-

-

-

7%

5%

11%

9%

Vitiligo

ORR overall response rate, PFS progression-free survival, OS overall survival, NSCLC non-small-cell lung cancer, RCC renal cell carcinoma. The three
most common adverse events are listed in order for each trial. AAt three varying dosages of nivolumab

Malignancy

# of
pts

Trial (Ref #)

Table 1. Summary of clinical trials investigating the use of nivolumab in various malignancies.
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separate study of 173 patients who had all previously been treated with ipilimumab
showed an overall response rate of 26% and median progression-free survival of 4.5
months with pembrolizumab treatment (50).
A subsequent phase II trial (KEYNOTE-002) was an international, randomized,
controlled trial comparing two pembrolizumab doses with investigator-choice
chemotherapy in patients with ipilimumab-refractory melanoma (51). The primary
endpoint was progression-free survival, which was found to be improved in patients
assigned to pembrolizumab 2 mg/kg (hazard ratio 0.57, 95% confidence interval (CI)
0.45 to 0.73) and those assigned to pembrolizumab 10 mg/kg (HR 0.5, 95% CI 0.39 to
0.64), compared with those assigned to chemotherapy. Median progression-free survival
was 4.9 months averaged amongst the two dosage groups of pembrolizumab, compared
to 2.6 months in the chemotherapy control group. The overall response rate with
pembrolizumab was 23% compared to only 4% in the investigator-choice chemotherapy
group.
Another large study compared the efficacy of pembrolizumab versus ipilimumab
in advanced melanoma patients (20). This study found a response rate of 33% in the
pembrolizumab group compared to 12% in the ipilimumab group. Furthermore, the
patients treated with pembrolizumab had longer progression-free survival and overall
survival, demonstrating that pembrolizumab has more clinical benefit compared to
ipilimumab. Estimated one-year survival rates were 71% and 58% with pembrolizumab
and ipilimumab, respectively.
In terms of lung cancer, only one clinical trial has been published. A large phase I
trial assessed the efficacy of pembrolizumab in 495 patients with advanced NSCLC (52).
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Among all patients, the objective response rate was found to be 19.4%, with a median
duration of response of 12.5 months and median progression-free survival of 3.7 months.
The median overall survival was 12 months. However, when looking at a subset of 73
patients who had PD-L1 expression in 50% or more of tumor cells, the response rate was
much improved to 45.2%, suggesting that there may be increased benefit in those patients
whose tumors strongly express PD-L1. Numerous other clinical trials studying the
efficacy of pembrolizumab in NSCLC are currently underway.
Based on the results of these trials, pembrolizumab was approved in 2014 for the
treatment of advanced melanoma after treatment with ipilimumab. In 2015,
pembrolizumab was granted accelerated approval for the treatment of metastatic NSCLC
in patients whose disease had progressed after other treatments and whose tumors
specifically expressed PD-L1. Table 2 summarizes the results of recent clinical trials
investigating pembrolizumab.

Anti-PD-1 Adverse Effects
The early phase I trial of nivolumab in previously treated melanoma patients
investigated safety in terms of overall adverse effects and those that were specifically
immune-related (38). The most common events of any grade included fatigue (32%), rash
(23%), and diarrhea (18%). In particular regards to immune-related events, this was quite
common as 54% of patients (58 of 107) experienced an irAE of any grade, but only 5%
were grade 3 or 4. The most common irAEs of any grade included skin disorders (36%),
gastrointestinal events (18%), and endocrinopathies (13%). Multiple other clinical trials
have found similar incidences of these adverse effects. Table 1 lists the three most
common adverse effects in each clinical trial, which include fatigue (ranging from 16 to

Melanoma

Melanoma

Melanoma

Melanoma
Melanoma
NSCLC

135

411

173

556
361
495

Hamid et al. 2013 (48)

Ribas et al. 2014 (49)

Robert et al. 2014 (50)

Robert et al. 2015
(Keynote 006) (20)

Ribas et al. 2015
(Keynote 002) (51)

Garon et al. 2015
(Keynote 001) (52)

19%

23%

33%

26%

34%

38%

ORR

3.7

4.9

4.8

4.5

5.9

>7

Median PFS
(mo)

12

Not yet
reported

Not
reached

Not
reached

Not
reached

Not
reached

Median
OS (mo)

Fatigue (35%)
Pruritus (23%)
Rash (18%)
Fatigue (20%)
Diarrhea (16%)
Pruritus (14%)
Fatigue (26%)
Pruritus (22%)
Rash (11%)
Fatigue (19%)
Pruritus (11%)
Decreased appetite (11%)

Fatigue (30%)
Rash (21%)
Pruritus (21%)
NR

Most Common Adverse
Events (% incidence)

10%

11%

14%

18%

NR

21%

Rash

11%

22%

14%

23%

NR

21%

Pruritus

-

5%

10%

7.5%

NR

9%

Vitiligo

ORR overall response rate, PFS progression-free survival, OS overall survival, NR not reported, NSCLC non-small-cell lung cancer. The three most common
adverse events are listed in order for each trial.

Malignancy

# of
pts

Trial (Ref #)

Table 2. Summary of clinical trials investigating the use of pembrolizumab in various malignancies.
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41%), decreased appetite (10 to 19%), gastrointestinal symptoms such as diarrhea (10 to
19%) and nausea (10 to 15%), and cutaneous manifestations such as rash and pruritus.
Rash appeared to be quite a common adverse effect of nivolumab, occurring in 4 to 27%
of patients. This is with the caveat that in these oncologic clinical trials, adverse effects
were tabulated separately as “rash” or as other more specific subsets such as “rash
maculopapular” or “rash erythematous.” Thus, the true incidence of any sort of rash may
be slightly higher than these numbers suggest. Pruritus was also reported in 2 to 19% of
patients.
Similar adverse effects and incidences have been found with pembrolizumab. In
the phase I study of patients with ipilimumab-refractory melanoma treated with
pembrolizumab, the most common drug-related adverse events of any grade were fatigue
(35%), pruritus (23%), and rash (18%) (50). Adverse events that were designated by the
investigators to be immune-related of any grade occurred in 24.5% of patients (25 of 173),
with the most common being hypothyroidism, diarrhea, arthralgia, and rash. Table 2
outlines the incidences of the most common adverse effects found in other clinical trials
of pembrolizumab, showing similar incidences to the above. Fatigue occurred in
anywhere between 19 to 35% of patients, rash in 10 to 21%, and pruritus in 11 to 23% of
patients. While rash was considered an immune-related adverse event, other common
irAEs seen with pembrolizumab included pneumonitis, colitis, and hypothyroidism and
other endocrine abnormalities (52).

PD-L1 Therapy
There are a few monoclonal antibodies directed against the PD-L1 ligand that
have been developed, including atezolizumab (also known as MPDL3280A) and MDX-
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1105 (also known as BMS-936559). These are currently being clinically investigated in
numerous malignancies. PD-1 inhibitors block both of the ligands PD-L1 and PD-L2, and
could theoretically provide more robust clinical efficacy but also increased toxicity. By
blocking PD-L1 further downstream in the pathway, this could lead to slightly decreased
anti-tumor response but also perhaps decreased toxicity. Preliminary data show that antiPD-L1 agents have clinical efficacy and seem to be well-tolerated in multiple cancers. In
an early study, 45 patients with melanoma were treated with atezolizumab as
monotherapy (53). A response rate of 26% (9 out of 35 patients) was observed, with all
responses ongoing or improving at time of analysis. Atezolizumab also appeared to be
well-tolerated, with no treatment-related deaths occurring on study and the most common
adverse effects being fatigue (59%), diarrhea (30%), and pruritus (25%). In a study of
207 patients with various malignancies, treatment was with MDX-1105, and the patient
group was comprised of 75 patients with NSCLC, 55 with melanoma, 18 with colorectal
cancer, 17 with RCC, 17 with ovarian cancer, 14 with pancreatic cancer, 7 with gastric
cancer, and 4 with breast cancer (54). An objective response was observed in 9 of 52
patients (17%) with melanoma, 2 of 17 patients (12%) with RCC, 5 of 49 (10%) with
NSCLC, and 1 of 17 (6%) with ovarian cancer. The most common adverse effects in this
study were fatigue occurring in 16% of patients, infusion-related reactions in 10% of
patients, and diarrhea in 9%. Rash and pruritus occurred in 7% and 6% of patients,
respectively. While this study showed objective response rates that are lower than the
large-scale trials of the anti-PD-1 agents nivolumab and pembrolizumab, whether or not
there is a true difference remains to be seen with further investigation and larger sample
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sizes. Further clinical trials regarding outcomes and adverse effects with anti-PD-L1
antibodies are currently underway.

Aims
While these anti-PD-1 and anti-PD-L1 therapeutic agents have shown activity in
numerous different malignancies, they have only emerged recently within the last several
years and remain relatively new. Thus, their safety and associated toxicity profiles are
still being fully characterized. Data from existing clinical trials show that a large
proportion of the associated adverse effects appear to be immune-related. These irAEs
further include a significant proportion that are cutaneous in nature. However, in the
large-scale oncologic trials evaluating anti-PD-1/PD-L1 agents, these cutaneous adverse
effects are described only as “rash.” Therefore, further investigation into the specific
characteristics of the cutaneous eruptions seen with these agents is warranted to
determine whether they are similar to or different from other drug eruptions. Doing so
will allow for early recognition by both oncologists and dermatologists alike and allow
for appropriate management and minimization of the impact of these skin toxicities. This
study sought to characterize both the clinical and histopathologic features of cutaneous
toxicities that developed in a series of patients receiving anti-PD-1 or PD-L1 therapy.

Methods
With the approval of the Yale University Institutional Review Board, cases were
collected from Yale-New Haven Hospital from between 2010 to 2015. Patients were
included if they were on treatment with either an anti-PD-1 or anti-PD-L1 agent alone, or
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if there were receiving an anti-PD-1 or anti-PD-L1 agent in combination with other
therapy, and if they were referred for dermatologic evaluation of rash. Data that was
collected included patient demographics, concurrent medications, therapeutic regimen,
type of disease, previous oncologic therapies, clinical morphology and distribution of
cutaneous lesions, treatment of rash, peripheral blood eosinophil count, and tumor
response. Consent was obtained from patients at time of their clinical evaluation to
document photographs of their cutaneous lesions, with minimization of any identifying
features. Concurrent medications at the time of presentation for each patient were
recorded. The peripheral blood eosinophil count was recorded at the time of biopsy, and
for those patients without biopsy, eosinophil count was recorded at the time of
presentation of cutaneous toxicity. Tumor response was determined from documentation
from the patients’ treating oncologists, and was characterized as one of four responses
based on RECIST (Response Evaluation Criteria in Solid Tumors) criteria: 1) complete
response, in which there is disappearance of all target lesions, 2) partial response in
which there is at least a 30% decrease in the sum of the size of target lesions, 3) stable
disease, in which there is neither sufficient shrinkage to qualify for partial response nor
sufficient increase to qualify for progressive disease, and 4) progressive disease, in which
there is at least a 20% increase in the sum of the size of target lesions or the appearance
of new lesions. Time to disease progression was calculated from the first dose of anti-PD1/PD-L1 treatment to progression, which was determined by imaging. Any other
immune-related adverse effects that were documented were recorded. The
histopathological features of available biopsy specimens were reviewed by two
dermatopathologists and tabulated. For each available case, light microscopic
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examination of tissue sections prepared with hematoxylin-eosin staining was performed.
In addition, for three of the cases (#2, 5, and 9), a panel of immunoperoxidase stains,
including stains for CD3, CD4, CD8, and CD20, was performed.

Results
A total of 20 patients were included in this study (13 men and 7 women). The
median age of patients at the onset of cutaneous toxicities was 62 years old (range 46 to
86 years). Ten patients were treated with nivolumab alone, while four were treated with
nivolumab in combination with ipilimumab. One patient was treated with nivolumab in
combination with bevacizumab, and one patient was started on nivolumab in addition to
erlotinib and subsequently continued on nivolumab alone. Two patients were treated with
pembrolizumab alone, one patient was treated with the anti-PD-L1 agent atezolizumab
alone, and one patient received atezolizumab in combination with carboplatin and
paclitaxel. 60% of patients (12 of 20) had received prior systemic therapy for their cancer,
with 3 of 20 patients having received prior immune checkpoint inhibitors. One of these
patients had already received a previous course of nivolumab and ipilimumab
combination therapy, while two patients had received therapy with ipilimumab. Table 3
summarizes the characteristics of the included patients.
The time of onset to cutaneous eruption was variable, with a mean time of 4
months and a range of 3 days to 13 months. The majority of cases (80%, 16 of 20) had a
clinical morphology consisting of erythematous papules with scale, in either a focal
distribution such as localized lesions on an extremity or the neck (55%, 11 of 20) (Figure
1A), or in a more generalized distribution of coalescing larger plaques on the trunk and
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TAC
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SD
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SD
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PD

PR

CR
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4.2B
3.9
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Table 3. Clinical and histologic profile of 20 patients with cutaneous adverse effects while receiving anti-PD-1/PD-L1 treatment.
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PFS progression-free survival, irAE immune-related adverse effect, C Caucasian, AA African-American, RCC renal cell carcinoma, MM malignant melanoma,
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Figure 1. Erythematous papules with scale due to anti-PD-1/PD-L1 therapy. A) Example
of localized lesions on the left forearm of a patient. B) Example of a generalized
distribution over the back.
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extremities (45%, 9 of 20) (Figure 1B). There were a few cases with distinct features.
One patient (#12) developed larger 1 to 2 cm keratotic scaly plaques on the lower legs
resembling hypertrophic lichen planus (Figure 2A). One patient (#7) had numerous pink
thin papules and plaques forming a shawl-like distribution over the upper chest (Figure
2B). One patient (#1) presented with scaly discrete papules on the back, chest, and
abdomen that looked typical of Grover’s disease, or transient acantholytic dermatosis. Of
note, two patients (#6 and 19) had lesions limited to a striking palmoplantar distribution
with additional oral mucosal lesions. In one of these patients (#6), there was a sudden
onset of small 2 to 3 mm pseudovesiculated papules in coalescent plaques covering the
palms and soles. On the soles, the plaques extended laterally onto the sides of the feet but
did not cross Wallace’s lines (Figure 2C). In the other patient (#19), pink-red scaly thin
papules limited to the palms and soles were larger (up to 1 cm), discrete, and not
coalescent (Figure 2D). One patient (#14) had distinct inflammation of and around
existing seborrheic keratoses (Figure 2E). One patient (#11) experienced within 5 days of
starting anti-PD-1 therapy, worsening of an existing rash that had started while on
previous treatment with ipilimumab. Four patients (#6, 9, 10, and 19) developed oral
lesions that varied in appearance. One patient (#6) developed concurrent 1 to 2 mm
whitish flat-topped papules with apparent Wickham’s striae on the bilateral buccal
mucosa extending onto the lateral commissures (Figure 2F), in addition to her
palmoplantar lesions. The other three patients (#9, 10, and 19) developed erosions
involving the tongue, buccal mucosa, lips, and/or gingivae. Lastly, one patient (#10)
developed erosive lesions on the penis, clinically resembling erosive lichen planus
(Figure 2G).
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Figure 2. Additional examples of cutaneous eruptions seen with anti-PD-1/PD-L1
therapy. A) Hypertrophic scaly papules and plaques on the lower extremity. B) Thin pink
papules and plaques in a shawl-like distribution over the upper chest. C) Coalescent
plaques localized to the sole of the foot. D) Scaly, discrete papules on the palm. E)
Inflammation of and around existing seborrheic keratoses on the back of a patient. F)
Small white papules on the buccal mucosa. G) Erosive lesions on the penis, resembling
erosive lichen planus.

26
Out of 20 patients, most (75%, 15 of 20) were noted to experience pruritus with
the lesions. The most common treatment was with topical corticosteroids. One patient
(#18) who developed two acute eruptions that appeared temporally related to erlotinib
administration required oral prednisone. The two patients who developed palmoplantar
lesions (#6 and 19) were treated with phototherapy, one with psoralen and ultraviolet A,
and the other with narrow band ultraviolet B, both with improvement. Five of 20 patients
(25%) required dose delay of the oncologic agent because of cutaneous toxicity.
Eosinophil counts were not significantly elevated in the majority of patients (80%, 16 of
20) at the time of cutaneous eruptions. Table 4 lists the concurrent medications at the
time of presentation and the absolute eosinophil counts in patients at time of biopsy or at
time of presentation if biopsy was not performed.
Tumor response, time to progression, and development of any other immunerelated adverse effects were also assessed (Table 3). Out of six patients with melanoma,
three had a partial response, one had stable disease, and two had progression of disease.
Out of 11 patients with NSCLC, two patients achieved complete response, seven had a
partial response, and two had progression of disease. Out of three patients with RCC, one
patient had a partial response, one patient had stable disease, and one patient had
progression of disease. Excluding three patients who had an ongoing response to
treatment at time of data collection, the mean progression-free survival (PFS) was 23.67
months, with a wide range between 1.73 to 75 months. This large range was due to a
distinct phenomenon of quite prolonged PFS in those patients who experienced tumor
response, compared to a much shorter PFS in patients who did not respond to treatment.
When separating patients into two groups, those who experienced an objective
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Table 4. Concurrent medications and peripheral eosinophil counts in patients.
Pt. #

Concurrent medications

1

Brimonidine, clopidogrel, cholecalciferol, CoQ10, iron,
loperamide, metformin, metoprolol, simvastatin,
tetrahydrozoline, nitroglycerin, aspirin
Aspirin, metformin, coumadin, amiodarone
Rosuvastatin, zolpidem
Insulin
Lorazepam, amlodipine, chlorthalidine, atenolol
Tiotropium, montelukast, metoprolol, HCTZ,
diphenhydramine
Hydrochlorothiazide, levothyroxine, tamsulosin
Tiotropium, ipratropium-albuterol, oxycontin, oxycodoneacetaminophen, alprazolam, fluticasone/salmeterol,
rosuvastatin, fenofibrate, aspirin
Ibuprofen
Omeprazole, prochlorperazine, sertraline, mirtazapine,
allopurinol, atorvastatin, naproxen
Aspirin, atorvastatin, glipizide, lisinopril, metformin,
metoprolol, nitroglycerin
Celecoxib, levetiracetam, phenobarbital, vitamin B12
Vitamin D
Aspirin, ibuprofen, omeprazole, zolpidem
Atorvastatin, cholecalciferol, colchicine, rivaroxaban,
famotidine, moxifloxacin
Aspirin, albuterol, famotidine, hydrocortisone, hydroxyzine,
lorazepam, omeprazole, zolpidem, levetiracetam
Lorazepam, mirtazapine, morphine
Sertraline, eszopiclone
Omeprazole, levothyroxine, bupropion, sertraline
Acetaminophen, atorvastatin, bupropion, tadalafil, digoxin,
fluticasone-salmeterol, metoprolol, morphine, omeprazole,
ondansetron, prochlorperazine, rivaroxaban, tiotropium

2
3
4
5
6
7
8

9
10
11
12
13
14
15
16
17
18
19
20

Serum eosinophils
(absolute count
cells/ul)
1050
104
504
0
212
252
747
138

84
72
930
135
310
126
304
150
66
208
159
0

Bolded medications indicate those that have been reported to cause lichenoid drug eruptions (55, 56).
Bolded eosinophil counts indicate those that represent a peripheral eosinophilia, defined as greater than 500
cells/ul.

response (either complete or partial), and those who experienced stable disease or
progression of disease, the mean PFS in each group was 33.8 months versus 5.1 months,
respectively.
Histology was available from 17 of the 20 patients. Nearly all cases (16 cases,
94%) showed features of lichenoid interface dermatitis (Figures 3A-C). In addition, many
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of the cases also showed features of spongiotic dermatitis (8 cases, 47%). One case, the
patient who developed acute eruptions in temporal association with erlotinib
administration (#18), showed evidence of vacuolar interface changes. Of the three
biopsies for which ancillary immunostaining was performed, all showed intradermal and
intraepithelial lymphocytes that were CD3-positive (Figure 3D). Intradermal
lymphocytes were CD4-positive, while intraepithelial lymphocytes were CD8-positive;
CD20 stains were negative (Figures 3E-G). Table 3 summarizes the predominant
histopathological patterns of each skin biopsy, and Table 5 summarizes the overall
findings seen in the series of cases.

Table 5. Summary of histologic features seen on biopsy of cutaneous eruptions
associated with anti-PD-1/PD-L1 therapy.
Reaction patterns

Diagnostic features

Additional finding

Interface dermatitis
Lichenoid
Vacuolar
Spongiotic dermatitis
Altered stratum corneum
Hyperkeratosis
Parakeratosis
Parakeratotic mounds
Serum deposition
Epidermal changes
Premature terminal differentiation
Acanthosis
Irregular psoriasiform hyperplasia
Atrophy
Superficial reticular dermal changes
Lymphocytic band-like
Mixed band-like
Mixed perivascular infiltrate
Lymphocytic perivascular
Stromal edema
Pigment incontinence
Red blood cell extravasation
Infundibulofolliculitis

Number
of cases
17
16
1
8
15
11
9
2
6
13
5
4
3
1
17
7
4
6
4
9
6
7
1

% of total
cases (n = 17)
100%
94%
6%
47%
88%
65%
53%
12%
35%
76%
29%
24%
18%
6%
100%
41%
24%
35%
24%
53%
35%
41%
6%
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Figure 3. Photomicrographs from one representative patient showing lichenoid interface
dermatitis (A-C; hematoxylin-eosin at 4x, 10x, and 20x respectively). Staining of
lymphocytic infiltrate with the following immunoprofile: CD3-positive (both intradermal
and intraepithelial lymphocytes, D), CD4-positive (intradermal lymphocytes, E), CD8positive (intraepithelial lymphocytes, F), and CD20-negative (G).
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Discussion
With recent advances in cancer therapy, immunotherapies have emerged as the
next generation of oncologic treatment. Antibodies that block either PD-1 or its ligand
PD-L1 have shown significant clinical activity and therapeutic promise. Because these
agents have just recently emerged within the last decade, their full toxicity profiles have
yet to be fully characterized. The main adverse effects that have been associated so far
with anti-PD-1 therapy include cutaneous toxicities, gastrointestinal symptoms such as
diarrhea or nausea, fatigue, myalgia, increased aminotransferase levels, and
hypothyroidism or other endocrinopathies (57). Cutaneous adverse effects most
commonly include rash (4 to 27% of patients), pruritus (2 to 23%), and less frequently
vitiligo (5 to 11%) (see Tables 1 and 2 for complete references), with comparable
incidences seen with pembrolizumab and nivolumab. Similar adverse effects are seen
with anti-PD-L1 antibodies and include fatigue (59%), diarrhea (30%), pruritus (25%),
and rash (16%) (53). These adverse effects are usually manageable and do not generally
require discontinuation of therapy.
While “rash” has been commonly reported as an adverse effect in many oncologic
trials evaluating anti-PD-1/PD-L1 antibodies, further details about the specific nature of
these cutaneous eruptions are often not completely described. Our study aimed to
characterize both the clinical and histologic features of cutaneous toxicities associated
with anti-PD-1/PD-L1 therapy. Our group of 20 patients represented a range of different
therapeutic regimens, consisting of 12 patients (60%) who were treated with anti-PD-1
monotherapy (either nivolumab or pembrolizumab alone), 4 patients (20%) who were
treated with combination therapy of nivolumab and ipilimumab, 2 patients (10%) who
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received PD-1 therapy (nivolumab) in addition to another agent of some kind, and 2
patients (10%) who were treated with anti-PD-L1 monotherapy with atezolizumab.
Despite the differences in treatment regimen, the cutaneous eruptions that were seen with
anti-PD-1, anti-PD-L1, or combination therapy shared common characteristics. Clinically,
the eruption seen with these agents consisted of erythematous scaly papules or plaques
that were usually pruritic. The distribution of lesions varied, with either a small number
of discrete papules or plaques on a limited area of the body or a generalized distribution
of larger plaques with a predilection for the trunk. A localized or generalized distribution
seemed to be relatively equally as likely, with an incidence of 55% and 45% in our group
of patients, respectively. There was also a wide range in time to cutaneous presentation
after initiation of anti-PD-1/PD-L1 therapy, ranging from 3 days to 13 months.
While the clinical morphology varied, the histology was remarkably consistent
amongst the patients. Nearly all of the cases for which biopsies were performed in our
study (16 out of 17, 94%) showed lichenoid interface changes. Three biopsies for which
immunohistochemical staining was available showed that this lichenoid infiltrate was
composed of predominantly CD4+ T cells within the dermis, with a few CD8+
intraepithelial lymphocytes. It is interesting to note that previous trials showed a CD8+ T
cell infiltrate within tumor metastases post-treatment (35, 36). In fact, one study in
particular found a greater increase in CD8+ density from baseline to post-treatment
biopsy that significantly correlated with a decrease in radiographic tumor size (58). Their
findings seemed to suggest that therapeutic PD-1 blockade was effective through CD8+ T
cells at the tumor margin. Our findings show a predominantly CD4+ T cell infiltrate,
suggesting that there may be different mechanism at play in the target tumor cells than in
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the skin. In addition, many of the biopsies showed concurrent features of spongiotic
dermatitis. These two features of lichenoid interface and spongiotic changes represent a
combination not commonly seen. A previous case series reported similar findings of
lichenoid dermatitis on histology in three patients receiving pembrolizumab for treatment
of melanoma (59). Clinically, the patients presented with papular lesions as well,
primarily on the trunk and extremities, between four to nine weeks after starting
treatment with pembrolizumab. Two of these patients had previously received
immunotherapy with ipilimumab. All three cases showed a CD3-positive lymphocytic
infiltrate, with a more prominent CD4+ component than CD8+, and with 10% of the T
cells showing positive PD-1 expression. Tumor response was noted in two of the three
patients, and consisted of one partial and one complete response. All three patients had
relatively mild toxicities, and oncologic treatment was not discontinued. In another recent
case series of 5 patients treated with anti-PD-1/PD-L1 agents, histologic examination
again revealed lichenoid dermatitis with greater histiocytic infiltrates, increased
spongiosis, and increased epidermal necrosis, compared to biopsies of non-drug-related
lichen planus (60). No significant differences were seen in CD4:CD8 ratio or in
expression of CD3, CD20, PD-1, CD25, Foxp3, CXCL13, or PD-L1 compared to the
control lichenoid reactions. Our results are consistent with this, showing a cutaneous
lichenoid eruption that is unique to anti-PD-1/PD-L1 therapy.
While PD-1 and PD-L1 inhibitors as monotherapy have shown remarkable
efficacy as anti-tumor agents, combination therapy with ipilimumab appears to have more
clinical benefit for patients with melanoma. A phase I trial in 53 melanoma patients
receiving the combination of nivolumab and ipilimumab showed a response rate of 40%,
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compared to a response rate of 20% in patients who had previously been treated with
ipilimumab who then received nivolumab monotherapy (61). Another phase I trial
studied 142 previously untreated patients with melanoma (62). These patients were
randomized to receive ipilimumab in combination with nivolumab or ipilimumab alone.
This study found an objective response rate of 61% in the group that received
combination therapy with ipilimumab and nivolumab versus 11% in the group that
received ipilimumab monotherapy, with the median progression-free survival not reached
with combination therapy and 4.4 months with ipilimumab monotherapy. A large-scale
trial of 945 previously untreated patients with melanoma randomized them in a 1:1:1
ratio to receive either nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone,
with progression-free survival and overall survival as coprimary endpoints (21). While
data on overall survival is not yet available, this study found significant differences in
progression-free survival. The median progression-free survival was 11.5 months (95%
confidence interval, 8.9 to 16.7) with nivolumab plus ipilimumab, as compared to 2.9
months (95% CI, 2.8 to 3.4) with ipilimumab alone, and 6.9 months (95% CI, 4.3 to 9.5)
with nivolumab alone. The patients were also broken down into subgroups depending on
whether their tumors were positive or negative for expression of PD-L1 ligand. In
patients with tumors positive for PD-L1, progression-free survival was 14 months with
both combination therapy and with nivolumab alone, but in patients with PD-L1-negative
tumors, PFS was longer with combination therapy than with nivolumab alone (11.2
month versus 5.3 months). Therefore, it appears that in the specific subset of patients
whose tumors do not strongly express PD-L1, combination therapy with ipilimumab and
a PD-1 inhibitor is more effective. Taken together, these trials show that there is

34
significant improvement in clinical efficacy with combination therapy, and that this may
be poised to become the next first-line treatment in melanoma.
However, combination therapy comes with a cost and that is a higher frequency of
irAEs. The most common adverse effects related to nivolumab and ipilimumab
combination therapy are rash (40 to 55% of patients), pruritus (33 to 47%), diarrhea (34
to 44%), and fatigue (35 to 38%) (21, 61). In addition to more frequent adverse effects, in
particular those that are cutaneous, combination immunotherapy also seems to lead to
increased severity of irAEs. One study found that the incidence of severe grade 3 or 4
adverse effects of any kind was 53% in patients on combination therapy, compared to
18% in patients on monotherapy with nivolumab (61). Another study found the incidence
of grade 3 or 4 adverse events to be 54% compared to 24% in patients treated with
ipilimumab alone (62). While our study only included four patients who were on
combination therapy with nivolumab and ipilimumab, there were no significant
qualitative differences amongst their cutaneous eruptions. They all developed papular
eruptions, although interestingly, one patient also developed inflammation of and
erythema around existing seborrheic keratoses. All the cutaneous eruptions were
relatively mild, and none of these four patients required discontinuation of their treatment
because of cutaneous toxicities. However, the caveat is that this sample size of four is
quite small, and it is also possible that those adverse effects that are more likely to be
severe may not be skin-related.
Given the use of these agents in oncologic patients, there is much interest in
determining whether there are predictors of which patients will respond to therapy.
Studies have suggested that expression of the ligand PD-L1 on tumor cells may be a
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possible marker of clinical response (63). In a clinical trial that investigated patients with
varying malignancies, none out of 17 patients with PD-L1-negative tumors had an
objective response to nivolumab, whereas 9 out of 25 patients (35%) with PD-L1-positive
tumors had an objective response (37). Another study aimed to look at tumor specimens
from 41 patients with varying cancers receiving nivolumab to explore components of the
tumor microenvironment (64). In this study, specimens with greater than 5% expression
on immunohistochemistry staining were considered “positive.” They found that when
positive tumor cell PD-L1 expression was observed, it was associated with infiltrating
immune cells including lymphocytes and histiocytes, and that the proportion of tumor
cells expressing PD-L1 correlated with the intensity of immune cell infiltration.
Furthermore, PD-L1 expression by tumor cells correlated significantly with objective
response and clinical benefit. However, the presence of immune cell infiltrates and level
of PD-L2 expression were not found to correlate with treatment response, suggesting that
while important, it may be PD-L1 expression itself that is more closely linked to clinical
response. Given the question of whether PD-L1 expression on tumor cells plays a
predictive role, a large meta-analysis aimed to pool data from multiple clinical trials.
Overall response rate was extracted from 20 phase I to III trials investigating nivolumab,
pembrolizumab, as well as atezolizumab. A significant interaction (p<0.0001) according
to tumor PD-L1 expression was found with an overall response rate of 34.1% in the PDL1 positive group and 19.9% in the PD-L1 negative group (65). While the results of these
various studies are certainly compelling, they do not explain the whole picture. What is
still true is that there are patients with PD-L1 negative tumors that do respond to anti-PD1 treatment, and the fact remains that the overwhelming majority of patients with PD-L1
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positivity do not respond. Furthermore, the CheckMate 066 study investigated nivolumab
in previously untreated melanoma patients and found a response rate of 52.6% (95% CI,
40.8 to 64.3) in the PD-L1 positive group compared to 33.1% (95% CI, 25.2 to 41.7) in
the PD-L1 negative group (39). While this may represent a trend towards some improved
clinical benefit with PD-L1 tumor expression, the authors of this study concluded that
given the magnitude of the clinical benefit in patients receiving nivolumab versus those
receiving dacarbazine, the comparison arm, PD-L1 status alone would not seem to be
useful in selecting patients for nivolumab treatment. There are further added
inconsistencies regarding measurement of PD-L1 expression that are assay related, in that
there is no clear consensus on which antibodies to use, which cells to stain, and what cutoff threshold to use. Therefore, there is still no reliable clinical characteristic or
laboratory parameter that can predict response to anti-PD-1/PD-L1 therapy.
With ipilimumab treatment, there is evidence that immune-related adverse effects
may be associated with response to therapy (66). A recent study sought to investigate this
idea with PD-1 therapy. This study of 83 patients treated with pembrolizumab found that
those patients who developed cutaneous adverse effects had significantly longer
progression-free survival, among three different groups receiving varying dosages of
pembrolizumab (57). One potential caveat, however, is that patients who progress
interrupt their treatment and do not receive the same cumulative dose, thereby having less
likelihood of developing adverse effects. A separate study investigated the association of
vitiligo with tumor response in patients with metastatic melanoma treated with
pembrolizumab (67). An objective complete or partial response to treatment was
associated with a higher occurrence of vitiligo: 12 of 17 patients (71%) who developed
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vitiligo had an objective tumor response, compared to 14 of 50 patients (28%) who did
not develop vitiligo (p=0.002). This study also found that those patients who developed
vitiligo had a higher frequency and severity of other irAEs. Another study of melanoma
patients treated with nivolumab found that rash and vitiligo correlated with statistically
significant differences in overall survival (68). This concept is intriguing, as cutaneous
adverse effects have been shown to be associated with likelihood of response to other
oncologic treatments, namely the rash seen with epidermal growth factor receptor
(EGFR) inhibitors (69, 70). Overall response rates with anti-PD-1/PD-L1 agents vary
with tumor type. As mentioned previously, the response rates in melanoma range
between 26 and 38% with pembrolizumab (48, 50), 31 to 44% with nivolumab (21, 38),
and approximately 25% with the anti-PD-L1 agent atezolizumab (53) (see Tables 1 and 2
for other references). Response rates in NSCLC range between 14 to 20% for nivolumab
(42, 43), and for pembrolizumab, the response rate was approximately 19% specifically
in patients whose tumors expressed PD-L1 (52). In RCC, response rates range between
20 to 29% with nivolumab (45, 46). Nivolumab and ipilimumab combination therapy is
known to result in greater response rates of up to 40 to 61% in melanoma patients (21, 61,
62). In our group, six patients with NSCLC were treated with monotherapy with either an
anti-PD-1 or PD-L1 agent alone; five of these patients (83%) showed a response. In
addition, out of four patients with melanoma treated with anti-PD-1 monotherapy, two
responded, and out of three patients with RCC, one responded. Of the two patients who
received nivolumab and ipilimumab combination therapy for advanced melanoma, one
responded and one had progression of disease. Given the small sample size of patients,
definitive conclusions about the association of cutaneous toxicities with tumor response
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in this group cannot be made. Six out of 20 patients (30%) developed other definitive
irAEs that were associated with anti-PD-1/PD-L1 therapy. Four of these six patients
showed a response to therapy, which may suggest a possible association between irAE
development and clinical response. Since the mechanism of PD-1 therapy essentially
stimulates an immune response, it is of great interest whether development of irAEs is
associated with clinical benefit, and this will need to be explored with further
investigation in large-scale trials.
Given that some patients in our study were on combination therapy, the question
arises of whether these cutaneous eruptions were truly due to anti-PD-1 therapy or
whether another drug might be responsible. Indeed, four of our patients were on
combination therapy with ipilimumab and nivolumab, and one might argue that the
clinical appearance of cutaneous eruptions from ipilimumab versus anti-PD-1 agents is
similar, consisting of erythematous papules coalescing into thin plaques. However,
ipilimumab eruptions have been associated with a concurrent increase in peripheral blood
eosinophil levels (26), and eosinophilia was not seen in the majority of patients in our
series or in the four patients who specifically received ipilimumab. Furthermore, the
changes on histology are distinct. In contrast to the superficial, perivascular CD4predominant infiltrate with eosinophils that is seen with ipilimumab therapy, biopsies
from our patients showed a lichenoid eruption. Lichenoid eruptions have not previously
been reported with ipilimumab, epidermal growth factor receptor (EGFR) inhibitors such
as erlotinib, bevacizumab, or traditional cytotoxic chemotherapies such as carboplatin or
paclitaxel. Thus, it seems likely that the lichenoid eruptions are associated with anti-PD-1
therapy. In addition, the clinical appearance and lichenoid changes on histology are
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consistently seen amongst both anti-PD-1 agents and anti-PD-L1 agents, supporting the
idea that this cutaneous reaction may be a direct, on-target effect of the PD-1/PD-L1
pathway rather than a nonspecific hypersensitivity reaction.
These findings may have implications for the pathogenesis of lichen planus (LP),
which is a T cell-mediated disease that affects the skin and mucous membranes, and
classically presents with flat-topped, red or purple-colored papules on the flexor surfaces
of extremities. LP can also affect the oral mucosa, and blockade of the PD-1/PD-L1
pathway significantly increases the proliferation of peripheral T cells in oral LP,
suggesting an inhibitory role of PD-1 (71). Just as LP presents with localized lesions,
perhaps the focal distribution seen in some of our patients suggests an underlying
“unmasking” of an immune response to a pre-existing antigen that is localized to a
specific site in the body. Only once is there blockade of the PD-1 pathway does the body
now produce an inflammatory response to this antigen. Histologically, LP also shows a
similar lichenoid interface dermatitis, with a dense, band-like lymphohistiocytic infiltrate
at the dermal-epidermal junction. LP can be difficult to distinguish from a lichenoid drug
reaction, which can show similar histologic changes, but features more suggestive of a
drug reaction include fewer epidermal changes and a higher concentration of necrotic
keratinocytes and eosinophils (55). Interestingly, the majority of patients in this series
were also on concurrent medications that have been reported in the literature to cause
lichenoid drug reactions (Table 4). Medications that have been reported to cause a
lichenoid drug reaction include anticonvulsants, allopurinol, anti-inflammatory drugs,
antimalarials, beta-blockers, diuretics, statins, and psychiatric drugs (55). However, these
patients had all previously tolerated these medications, and the fact that anti-PD-1/PD-L1
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therapy was the only new medication for these patients suggests it is the most likely drug
culprit. It is possible that the administration of an anti-PD-1 or PD-L1 therapeutic agent
may also further “unmask” an immune response to a medication that was previously
tolerated, resulting in these lichenoid eruptions. Interestingly, one patient (#18)
developed acute rashes that seemed to be temporally related to erlotinib administration,
even though she had previously tolerated a course of erlotinib with no issues two years
prior, possibly representing an activation of the immune system by anti-PD-1 therapy to
mount a more exuberant inflammatory response.
In summary, the cutaneous eruptions described in this study represent a unique
adverse effect associated with anti-PD-1 therapy that is typically papular in morphology
with associated scale and pruritus. There appears to be a spectrum of clinical
presentations and distributions, ranging from one or two localized lesions on an extremity
to a more generalized, diffuse eruption. Yet, a lichenoid pattern on histology appears to
predominate. The eruptions are usually relatively mild and typically can be adequately
managed with topical corticosteroids. The cutaneous reaction associated with anti-PD1/PD-L1 therapy appears to have distinct clinical and histologic features compared to
other immunotherapies. Further investigation is needed to determine whether there is an
association between cutaneous adverse effects or other irAEs and tumor response. This
series of patients adds further characterization to the emerging toxicity profiles of antiPD-1/PD-L1 therapies.
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